Dr’s Fluge and Mella had produced a breakthrough and they had a new problem. Over 60% of the ME/CFS patients they gave the powerful immune drug Rituximab significantly improved but they tended to relapse when they were off the drug. Plus some patients didn’t react to the drug.
In this study the two Norwegian doctors a) tested the drug on more patients, b) tried to make the improvements permanent and c) have more patients repond.
Rituximab is the hottest treatment possibility out there. Check out how it did in it’s second major trial and see what’s next in the Rituximab/ME/CFS saga in the Simmaron Research Foundation sponsored blog